➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
Baxter
Harvard Business School
McKesson
Mallinckrodt

Last Updated: September 29, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for QGC001

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for QGC001?

QGC001 is an investigational drug.

There have been 8 clinical trials for QGC001. The most recent clinical trial was a Phase 2 trial, which was initiated on March 1st 2020.

The most common disease conditions in clinical trials are Hypertension, Ventricular Dysfunction, Left, and Ventricular Dysfunction. The leading clinical trial sponsors are Quantum Genomics SA, Quotient Sciences, and [disabled in preview].

There are three US patents protecting this investigational drug and forty-seven international patents.

Recent Clinical Trials for QGC001
TitleSponsorPhase
Firibastat in Treatment-resistant HypertensionQuantum Genomics SAPhase 3
Evaluation of the PK Profile of Firibastat Following Administration of Firibastat Prototype Tablet FormulationsQuotient SciencesPhase 1
Evaluation of the PK Profile of Firibastat Following Administration of Firibastat Prototype Tablet FormulationsQuantum Genomics SAPhase 1

See all QGC001 clinical trials

Clinical Trial Summary for QGC001

Top disease conditions for QGC001
Top clinical trial sponsors for QGC001

See all QGC001 clinical trials

US Patents for QGC001

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
QGC001   Start Trial Derivatives of 4,4'-dithiobis-(3-aminobutane-1-sulfonates) and compositions comprising the same Institute National de la Sante et de la Recherche Medicale (Inserm) (Paris Cedex, FR)   Start Trial
QGC001   Start Trial Method for the preparation of (3S, 3S') 4,4'-disulfanediylbis (3-aminobutane 1-sulfonic acid) QUANTUM GENOMICS (Paris, FR)   Start Trial
QGC001   Start Trial Method for the preparation of (3S,3S') 4,4'-disulfanediylbis (3-aminobutane 1-sulfonic acid) QUANTUM GENOMICS (Massy, FR)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
Baxter
Harvard Business School
McKesson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.